Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
India has many beautiful valleys filled with greenery, rivers, and mountains. Some of these valleys…
Federation of Indian Chambers of Commerce and Industry (FICCI) has appointed the Anant Swarup as…
Honorable Chief Minister of the Andhra Pradesh N. Chandrababu Naidu has launched the Amaravati Quantum…
Melie Kerr the captain of the New Zealand women team has been named the ICC…
T20 World Cup 2026 Player of the Tournament Sanju Samson has been awarded the ICC…
Money is very important in our daily lives. Every country usually has its own currency,…